Home - Products - Cell Cycle/DNA Damage - Integrin - Elarofiban TFA

Elarofiban TFA

CAS No. 198958-89-3

Elarofiban TFA( —— )

Catalog No. M34234 CAS No. 198958-89-3

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	296	Get Quote
5MG	459	Get Quote
10MG	657	Get Quote
25MG	994	Get Quote
50MG	1371	Get Quote
100MG	1773	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Elarofiban TFA
Note

Research use only, not for human use.
Brief Description

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
Description

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

Integrin
Recptor

Integrin
Research Area

——
Indication

——

Chemical Information

CAS Number

198958-89-3
Formula Weight

644.56
Molecular Formula

C26H34F6N4O8
Purity

>98% (HPLC)
Solubility

——
SMILES

OC(C(F)(F)F)=O.O=C([C@H]1CN(CCC1)C(CCC2CCNCC2)=O)N[C@H](C3=CN=CC=C3)CC(O)=O.OC(C(F)(F)F)=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Lifitegrast

A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG.
Gantofiban

Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.
Cilengitide trifluor...

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Sign In Join Free